Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Formulations recombinant

Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment... [Pg.1323]

Scharrer I, Brackmann HH, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000 6(6) 614-18. [Pg.1324]

Vaccine candidates are based on the two viral surface proteins, gD and gB (80). Recombinant methods are used to express the proteins, either in Chinese hamster ovary (CHO) cells or in baculovims. The proteins are purified as subunits and formulated with different adjuvants. Clinical trials with these vaccine candidates have been performed, but the results to date have not been encouraging. [Pg.359]

The second example is the SE-HPLC analysis of recombinant hGH. In this example, SE-HPLC is used for both a purity and a protein concentration method for bulk and formulated finished products. This method selectively separates both low molecular weight excipient materials and high molecular weight dimer and aggregate forms of hGH from monomeric hGH, as shown... [Pg.533]

FIGURE 18.2 Typical chromatogram (baseline view) of finished product recombinant hGH formulation. This method is performed with a TSK GEL G3000SW column. [Pg.534]

The nasal tissue is highly vascularized and provides efficient systemic absorption. Compared with oral or subcutaneous administration, nasal administration enhances bioavailability and improves safety and efficacy. Chitosan enhances the absorption of proteins and peptide drugs across nasal and intestinal epithelia. Gogev et al. demonstrated that the soluble formulation of glycol chitosan has potential usefulness as an intranasal adjuvant for recombinant viral vector vaccines in cattle [276]. [Pg.189]

Factor IX Replacement Hemophilia B therapy may include recombinant (produced via transfection of mammalian cells with the human factor IX gene) or plasma-derived (concentrate from pooled plasma) factor IX (see Table 64-2). Guidelines for choosing the factor-concentrate formulation for hemophilia B are similar to the guidelines for hemophilia A. However, older-generation factor IX concentrates containing other vitamin K-dependent proteins (e.g., factors II, VII, and IX), called prothrombin complex concentrates (PCCs), have been associated with thrombogenic side effects. Consequently, these products are not first-line treatment for hemophilia B.11... [Pg.990]

Hepatitis B vaccine is manufactured using recombinant DNA technology to express hepatitis B surface antigen (HBsAg) in yeast. This is further purified with biochemical separation techniques to produce the vaccine. The vaccines are formulated to contain 10 to 40 meg of HBsAg protein/mL. Hepatitis B vaccine is available as a single component or in combination vaccines. [Pg.1243]

J. L. Cleland and A. J. Jones, Stable formulations of recombinant human growth hormone and interferon-y for microencapsulation in biodegradable microspheres, Phar. Res, 13(10), 1464 (1996). [Pg.721]

However, this formulation yields very little information on the actual course of the reaction, i.e. of which partial processes it consists. This set of partial processes is termed the mechanism of the electrode reaction. In the first case, the electrode reaction at some electrodes involves the formation of an adsorbed hydrogen atom, followed by the recombination reaction ... [Pg.261]

Rebif is produced via recombinant DNA technology in a CHO cell line. It displays an identical amino acid sequence to that of native human IFN-P-la and, like the native product, is glycosylated. After cell culture the interferon is purified using a series of chromatographic steps (affinity, ion-exchange, gel-filtration and reverse-phase liquid chromatography). It is formulated as a sterile solution in pre-filled syringes and contains mannitol, HSA, sodium acetate, acetic acid and sodium hydroxide as excipients. It is administered subcutaneously three times weekly. [Pg.230]

Actrapid/Velosulin/ Monotard/ Insulatard/ Protaphane/ Mixtard/ Actraphane/ All contain recombinant human insulin produced in S. cerevisiae formulated as short/ intermediate/long acting product) Identical to native human insulin Novo Nordisk 2002 (EU)... [Pg.298]


See other pages where Formulations recombinant is mentioned: [Pg.311]    [Pg.79]    [Pg.1840]    [Pg.311]    [Pg.79]    [Pg.1840]    [Pg.308]    [Pg.297]    [Pg.532]    [Pg.297]    [Pg.433]    [Pg.579]    [Pg.644]    [Pg.458]    [Pg.1523]    [Pg.77]    [Pg.143]    [Pg.168]    [Pg.706]    [Pg.712]    [Pg.717]    [Pg.719]    [Pg.21]    [Pg.220]    [Pg.172]    [Pg.508]    [Pg.529]    [Pg.54]    [Pg.85]    [Pg.139]    [Pg.143]    [Pg.226]    [Pg.78]    [Pg.246]    [Pg.250]    [Pg.271]    [Pg.302]    [Pg.303]    [Pg.304]    [Pg.324]    [Pg.325]    [Pg.63]   
See also in sourсe #XX -- [ Pg.258 ]




SEARCH



© 2024 chempedia.info